论文部分内容阅读
目的观察依达拉奉对急性心肌梗死再灌注损伤心肌的保护作用。方法68例急性心肌梗死(AMI)患者分为治疗组35例,对照组33例,治疗组采用国产尿激酶静脉点滴并用依达拉奉静脉滴注,对照组采用国产尿激酶静脉点滴。治疗48 h后查血清丙二醛(MDA)含量,并观察两组患者的冠脉再通率、心律失常发生率、7 d再梗死率、5周病死率及各种不良反应。结果治疗48 h后,治疗组MDA含量为(3.12±0.14)μmol/L,对照组MDA为(4.12±0.11)μmol/L,差异有统计学意义(P<0.05);治疗组心律失常发生率、7 d后再梗死率及5周病死率均低于对照组,差异有统计学意义;两组冠状动脉再通率相似。结论依达拉奉可减轻AMI溶栓后的再灌注损伤,对缺血心肌有保护作用。
Objective To observe the protective effect of edaravone on myocardium after reperfusion injury in acute myocardial infarction. Methods Sixty-eight AMI patients were divided into treatment group (n = 35) and control group (n = 33). The patients in the treatment group were given intravenous drip of domestic urokinase and edaravone intravenously. The control group was intravenously administered with domestic urokinase. Serum malondialdehyde (MDA) content was measured 48 hours after treatment. The coronary recanalization rate, arrhythmia incidence, 7-day re-infarction rate, 5-week mortality and various adverse reactions were observed in both groups. Results After treatment for 48 h, the MDA content in the treatment group was (3.12 ± 0.14) μmol / L and that in the control group was (4.12 ± 0.11) μmol / L, the difference was statistically significant (P <0.05); The incidence of arrhythmia , 7-day infarction rate and 5-week mortality were lower than the control group, the difference was statistically significant; two groups of coronary recanalization rates were similar. Conclusion Edaravone can reduce the reperfusion injury after AMI thrombolytic therapy, and has a protective effect on ischemic myocardium.